Search Results for "nafcillin"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for nafcillin. Results 1 to 6 of 6 total matches.

Table: Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023  (Issue 1669)
nafcillin nevirapine oritavancin oxcarbazepine phenobarbital* phenytoin derivatives* primidone ...
View the Inhibitors and Inducers of CYP Enzymes, P-Glycoprotein, and Other Transporters tables
Med Lett Drugs Ther. 2023 Feb 6;65(1669):e28-30   doi:10.58347/tml.2023.1669g |  Show IntroductionHide Introduction

Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025  (Issue 1737)
with cefazolin or an antistaphylococcal penicillin such as nafcillin.1 ABSSSI – Patients hospitalized ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSIs), and community-acquired bacterial pneumonia (CABP) (see Table 1). It is the second cephalosporin with activity against methicillin-resistant S. aureus (MRSA) to be approved in the US; ceftaroline (Teflaro), which was approved for treatment of ABSSSIs and CABP in 2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52   doi:10.58347/tml.2025.1737d |  Show IntroductionHide Introduction

Opill — An OTC Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
-rifampin antibiotics (except possibly nafcillin and dicloxacillin) does not reduce the efficacy ...
The FDA has approved Opill (Perrigo), a progestin-only oral contraceptive that contains norgestrel, for sale over the counter (OTC). Opill is the first oral contraceptive to be approved in the US for sale without a prescription. Approval of OTC Opill is intended to increase access to effective contraception and reduce the rate of unintended pregnancies.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):151-2   doi:10.58347/tml.2023.1685c |  Show IntroductionHide Introduction

Comparison Table: Some Oral Anticoagulants for VTE (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
, nafcillin, phenytoin, rifampin, St. John’s wort, and sucralfate can decrease the anticoagulant effect ...
View the Comparison Table: Some Oral Anticoagulants for VTE
Med Lett Drugs Ther. 2022 Jul 25;64(1655):e122-4 |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
, nafcillin, phenytoin, rifampin, St. John’s wort, and sucralfate can decrease the anticoagulant effect ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Choice of Contraceptives

   
The Medical Letter on Drugs and Therapeutics • May 15, 2023  (Issue 1676)
nafcillin and dicloxacillin) does not reduce the efficacy of hormonal contraceptives.18 PROGESTIN-ONLY ...
Intrauterine devices (IUDs) and the etonogestrel implant are the most effective reversible contraceptive methods available. Hormonal oral contraceptives, patches, rings, and injectables are also effective in preventing pregnancy. When used alone, barrier and behavioral methods generally have higher failure rates than other methods (see Table 1). Selection of a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80   doi:10.58347/tml.2023.1676a |  Show IntroductionHide Introduction